16 December 2024 07:00
GMT
Non-Executive Board
Appointments
AstraZeneca PLC announced today that
Rene Haas and Birgit Conix have been appointed as Non-Executive
Directors with effect from 1 January 2025 and 1 February 2025
respectively.
Birgit will become a member of the
Audit Committee on appointment to the Board.
Rene is Chief Executive Officer of
Arm. Birgit is Chief Financial Officer of Sonova. Further
biographical details are set out below.
Michel Demaré, Chair of AstraZeneca,
said "I am confident Rene and Birgit will be excellent additions to
the AstraZeneca Board. We look forward to welcoming them as
we continue the process of refreshing the Board in anticipation of
four current Non-Executive Directors reaching nine years' tenure in
the coming years.
"Rene brings deep and broad
knowledge of technology including data science, computing and AI
from his numerous years' experience in the microprocessor,
semiconductor and software engineering industry, and experience of
leading a large Cambridge, UK-based technology company.
"Birgit's financial and executive
experience through successive CFO roles over the last decade,
together with her 15 years' experience of the pharmaceutical
industry prior to that, will enable her to contribute to the Audit
Committee's and Board's work from the outset.
"Both Rene and Birgit bring to
AstraZeneca's Board significant international experience in senior
executive roles at large global businesses."
Biographical details - Rene
Haas
Rene was appointed Chief Executive
Officer and to the Arm Board in February 2022. In September
2023, he led Arm's return to the public markets with the most
valuable IPO of the year. Prior to becoming CEO, Rene was
President of Arm's IP Product Groups (IPG) from January 2017.
Under his leadership, he transformed IPG to focus on key solutions
for vertical markets with a more diversified product portfolio and
increased investment in the Arm software ecosystem. Rene
joined Arm in October 2013 as Vice President of Strategic Alliances
and two years later was appointed to the Executive Committee and
named Arm's Chief Commercial Officer in charge of global sales and
marketing.
Before joining Arm, Rene held
several applications management, applications engineering and
product engineering roles, including seven years at NVIDIA as Vice
President and General Manager of its computing products
business. Prior to NVIDIA, Rene held executive roles at
Scintera Networks and Tensilica.
In addition to his role as CEO of
Arm, Rene also sits on the Boards of Arm China and SoftBank
Group.
Rene is based in Silicon Valley, US
and also spends significant time in the major technology centres of
the UK, Europe and Asia Pacific.
Rene earned his Bachelor of Science
in Electrical and Electronics Engineering from Clarkson University
and is a graduate of the Stanford University Graduate School of
Business Executive Education Program.
Biographical details - Birgit
Conix
Birgit joined Sonova and became
Chief Financial Officer and a member of the Management Board in
2021. She was previously Chief Financial Officer and member
of the Executive Board of TUI, a global leader in tourism, from
2018 to 2021. Before joining TUI, she was Chief Financial
Officer of the Belgian media, cable and telecommunications business
Telenet Group from 2013 until 2018. Prior to that, she held
various senior positions in finance, strategy and business
operations in the pharmaceuticals and medical devices business
units at Johnson & Johnson, and in finance at Heineken, Tenneco
and Reed Elsevier.
In addition to her role as CFO of
Sonova, Birgit is a member of the Supervisory Board of ASML, one of
the world's leading manufacturers of chip-making equipment in the
semiconductor industry, where she is Chair of the ESG Committee and
a member of the Audit Committee.
Birgit holds an MBA from the Booth
School of Business, University of Chicago and a Master of Science
in Business Economics from the University of Tilburg.
Except as set out above, no
disclosure obligations arise under paragraphs (1) to (6) of UKLR
6.4.8 R of the UK Financial Conduct Authority's Listing Rules in
respect of these appointments.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is
a global, science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC